Abstract 1325P
Background
Sunvozertinib (DZD9008) is a rationally designed, irreversible EGFR inhibitor targeting EGFR mutations with wild-type EGFR selectivity. Primary analysis of two ongoing pivotal studies (WU-KONG1 [NCT03974022] and WU-KONG6 [NCT05712902 & CTR20211009]) have demonstrated promising efficacy and safety of sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion mutations (exon20ins) in ≥ 2nd line settings. Herein, we reported preliminary results of sunvozertinib in treatment naïve EGFR exon20ins NSCLC.
Methods
NSCLC patients with EGFR exon20ins who did not receive prior systemic anti-cancer therapy were enrolled into two ongoing studies: WU-KONG1, a multinational phase I/II study; and WU-KONG15 (NCT05559645), a phase II investigator-initiated study. Sunvozertinib was administered orally at 200 mg or 300 mg QD until discontinuation criteria were met. Efficacy analysis included patients with at least one post-treatment tumor assessment according to RECIST 1.1 by independent review committee (IRC).
Results
As of February 21, 2023, a total of 28 patients were included in the efficacy analysis (200 mg, n = 19; 300 mg, n = 9). Median age was 67 years, and 75.0% (21/28) were female. Baseline ECOG PS was 0 or 1. Majority of patients (96.4%, 27/28) had metastatic diseases at study entry, with 21.4% (6/28) having > 3 metastatic sites and 32.1% (9/28) having baseline brain metastasis (BM). The most frequent mutation subtypes included 769_ASV (39.3%, 11/28), 770_SVD (10.7%, 3/28) and others. By IRC, 20 patients achieved tumor response, with a best objective response rate (ORR) of 71.4% (200 mg, 68.4%; 300 mg, 77.8%). Median duration of response has not been reached. Safety findings were consistent with results of previous sunvozertinib studies. The most common TEAEs included diarrhea, CPK increase, and skin rash. Majority of the AEs were of CTCAE grade 1 or 2, and clinically manageable.
Conclusions
In the 1st line setting, sunvozertinib as monotherapy demonstrated promising anti-tumor efficacy and acceptable safety profile in NSCLC patients with EGFR exon20ins. A phase III, multinational, randomized study (WU-KONG28, NCT05668988) is ongoing to compare sunvozertinib to chemotherapy as 1st line treatment for EGFR exon20ins NSCLC.
Clinical trial identification
NCT03974022, NCT05559645.
Editorial acknowledgement
Legal entity responsible for the study
Dizal Pharmaceutical.
Funding
Dizal Pharmaceutical.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19